Search hospitals > Minnesota > Duluth
Miller-Dwan Hospital
Claim this profileDuluth, Minnesota 55805
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
307 reported clinical trials
2 medical researchers
Summary
Miller-Dwan Hospital is a medical facility located in Duluth, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Miller-Dwan Hospital is involved with conducting 307 clinical trials across 398 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Bret E. FridayEssentia Health Cancer Center5 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
109 reported clinical trials
180 drugs studied
Bret EB FridayEssentia Health - Deer River Clinic5 years of reported clinical research
Studies Glioblastoma
Studies Cognitive Impairment
2 reported clinical trials
1 drug studied
Clinical Trials running at Miller-Dwan Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Cancer
Bladder Cancer
Squamous Cell Carcinoma
Cutaneous Melanoma
Prostate Cancer
Melanoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Miller-Dwan Hospital?
Miller-Dwan Hospital is a medical facility located in Duluth, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Miller-Dwan Hospital is involved with conducting 307 clinical trials across 398 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.